Publication Name	World Journal of Hepatology
Manuscript ID	2594
Country	United States

Received	2013-03-03 15:31
Peer-Review Started	2013-03-03 18:20
To Make the First Decision	2013-03-11 15:01
Return for Revision	2013-03-14 09:10
Revised	2013-03-19 02:58
Second Decision	2013-05-17 14:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-05-18 00:23
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-06-18 12:06
Publish the Manuscript Online	2013-06-27 17:20

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Case Report
Article Title	Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Harrys A Torres, Parag Mahale, Ethan D Miller, Thein H Oo, Catherine Frenette and Ahmed O Kaseb
Funding Agency and Grant Number
Corresponding Author	Harrys A Torres, MD, FACP, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. htorres@mdanderson.org
Key Words	Hepatitis C virus; Cancer; Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Telaprevir; Interactions
Core Tip	This case suggests that therapy for chronic hepatitis C virus (HCV) infection may be given simultaneously with localized chemotherapy in patients with hepatocellular carcinoma (HCC). The use of telaprevir has improved response rates in patients with HCV genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein, we describe a patient with HCV-associated HCC treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization). No clinically relevant interactions or adverse events developed while on antiviral therapy.
Publish Date	2013-06-27 17:20
Citation	Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 2013; 5(6): 332-335
URL	http://www.wjgnet.com/1948-5182/full/v5/i6/332.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i6.332

Full Article (PDF)	WJH-5-332.pdf
Manuscript File	2594-Review.doc
Answering Reviewers	2594-Answering reviewers.doc
Copyright License Agreement	2594-Copyright assignment.pdf
Peer-review Report	2594-Peer review(s).pdf
Scientific Editor Work List	2594-Scientific editor work list.doc